Christopher John Tovey BSc — Chief Operating Officer at GW Pharmaceuticals

Mr. Christopher John Tovey, also known as Chris, BSc has been the Chief Operating Officer at GW Pharmaceuticals plc since October 2012. Mr. Tovey has gained a wealth of commercial experience from more than 25 years in the pharmaceutical industry. He served as Vice President of Global Marketing Operations at UCB Pharmaceuticals, responsible for worldwide marketing activities on a portfolio of UCB products generating over ???2 billion in annual sales. This portfolio encompassed a broad range of therapeutic areas (including epilepsy, other CNS, cardiovascular, anaemia, allergy) spread across most regions of the world and involved working with a wide range of internal and external commercial partners. Combined with this role, he also had responsibility for leading Global Digital Marketing at UCB. Previous experience and roles at UCB included two years spent as Managing Director Greece and Cyprus and prior to that a role leading all UCB activities on the orphan narcotic medication Xyrem, used in the treatment of Narcolepsy. Prior to joining UCB, Mr. Tovey was Vice President Managing Director UK & Ireland at Nabi Biopharmaceuticals, a US based biopharmaceutical company. He served as Country Manager of Nabi Biopharmaceuticals UK Limited of Nabi Biopharmaceuticals since September 2005. He led the European launches at StaphVAX. Before joining Nabi, he spent 18 years at GlaxoSmithKline, in senior commercial roles in both the European and UK organisations. These roles included Director of Commercial Strategy Distribution Europe, Director of European Vaccine Therapy, Director of Commercial Development UK, Director of Vaccines Business Unit UK and Business Unit Manager of Oncology UK. Whilst at GSK, he worked across a wide range of therapeutic areas including Infectious diseases, Neurology, Oncology, Diabetes, Respiratory and Immunology. He served as an Executive Director of GW Pharmaceuticals plc since October 1, 2012. He led pan European commercialisation efforts for a broad range of adult and paediatric vaccines, including Infanrix???, Engerix???-B and Havrix???, as well as leading sales efforts for antibiotic products for infectious diseases and Staphylococcal infections, including Augmentin???, Zinnat???, Timentin???, and Bactroban???. Mr. Tovey received a Bachelor of Science degree in Marine Biology from the University of Liverpool, UK.